Challenging Cases in BRAF-Mutated Melanoma: Applying the Latest Advances to Optimize Care

Released On
December 22, 2021

Expires On
December 21, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology, Dermatology

Topic(s)
Oncology, BRAF, Melanoma

Scroll to the Bottom of this Information to Begin this Course

This continuing medical education activity is provided by:

 

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with cutaneous melanoma.

Program Overview

Advances in BRAF-targeted agents and their integration into treatment algorithms for patients with BRAF-mutated melanoma have dramatically enhanced clinical outcomes. Although the rapid expansion in available treatment options has improved patient outcomes, physicians are now challenged to select from multiple classes of therapies and combinations, particularly with the increased use of triple therapy regimens combining PD-1 blockade with BRAF/MEK inhibitors. Additionally, the optimal sequencing of regimens for treating advanced BRAF-mutated melanoma remains an active area of investigation. In this case-based educational activity, experts will review clinical examples that highlight patients with BRAF-positive melanoma who may benefit from neoadjuvant and/or adjuvant treatment. Faculty will also discuss the latest evidence regarding the use of triple therapy for patients with BRAF-mutated melanoma as well as updates on the management of patients with brain metastases.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate patients with BRAF-positive melanoma who may benefit from neoadjuvant and/or adjuvant treatment.
  • Assess the latest evidence regarding the use of triple therapy combinations for patients with BRAF-positive melanoma and how these strategies may fit into existing treatment paradigms.
  • Examine the latest evidence regarding the burden of brain metastases in patients with advanced melanoma.

 

Activity Chair

FACULTY_NAME

Adil Daud, MD, MBBS

Professor of Medicine
Director, Melanoma Clinical Research
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Faculty

FACULTY_NAME

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Departments of Translational Molecular Pathology and Systems Biology
The Anne and John Mendelsohn Chair for Cancer Research
The University of Texas MD Anderson Cancer Center
Houston, TX

 

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Physician Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Vindico Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s):

Adil Daud, MD, MBBS
  • Advisor: Amgen, Bristol-Myers Squibb, Checkmate, Incyte, Merck, Novartis, Pfizer, Roche/Genentech
  • Consultant : Bristol-Myers Squibb
Michael A. Davies, MD, PhD
  • Consultant : ABM Therapeutics, Apexigen, Array/Pfizer, Bristol-Myers Squibb, Eisai, Novartis, Roche/Genentech
  • Independent Research Contractor : Array/Pfizer

Reviewer reports the following relevant financial relationship(s):

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP: No relevant financial relationships to disclose.

Vindico Medical Education Staff reports the following relevant financial relationship(s): No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Unlabeled and Investigational Usage:

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Copyright Statement:

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information

For CME questions please contact: CME@VindicoCME.com